Ifosfamide

Generic Name: Ifosfamide

Brand Names: Ifex

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 3778-73-2

Unique Ingredient Identifier: UM20QQM95Y

Background: Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication: Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.

Associated Conditions: Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma

Associated Therapies: -

Clinical Trials

Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

Phase 3

Conditions: Leukemia

Interventions: Drug: asparaginase
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: daunorubicin hydrochloride
Drug: doxorubicin hydrochloride
Drug: methotrexate
Drug: mercaptopurine
Drug: thioguanine
Drug: etoposide
Drug: vincristine sulfate
Drug: ifosfamide
Drug: leucovorin calcium
Drug: prednisone
Drug: vindesine

First Posted Date: 2008-10-02

Last Posted Date: 2009-07-08

Lead Sponsor: University Hospital, Motol

Target Recruit Count: 4000

Registration Number: NCT00764907

Locations: 🇨🇿
University Hospital Motol, Prague, Czech Republic

Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

Phase 1

Completed

Conditions: Sarcoma

Interventions: Drug: cisplatin
Drug: dexrazoxane hydrochloride
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: leucovorin calcium
Drug: methotrexate
Drug: zoledronic acid
Procedure: adjuvant therapy
Procedure: neoadjuvant therapy
Procedure: therapeutic conventional surgery
Biological: filgrastim
Drug: Mesna

First Posted Date: 2008-08-28

Last Posted Date: 2014-07-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 24

Registration Number: NCT00742924

Locations: 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States
🇺🇸
Maine Children's Cancer Program at Barbara Bush Children's Hospital, Scarborough, Maine, United States

and more 85 locations

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

First Posted Date: 2008-07-22

Last Posted Date: 2020-04-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 63

Registration Number: NCT00720109

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Valley Children's Hospital, Madera, California, United States

and more 131 locations

Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors

Not Applicable

Suspended

Conditions: Chemotherapeutic Agent Toxicity
Renal Toxicity
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2008-06-11

Last Posted Date: 2014-11-05

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 80

Registration Number: NCT00695032

Locations: 🇫🇷
Institut Claudius Regaud, Toulouse, France

Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma

Not Applicable

Conditions: Lymphoma

Interventions: Biological: rituximab
Biological: filgrastim
Biological: bleomycin sulfate
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisolone
Drug: vincristine sulfate
Drug: etoposide phosphate
Drug: methotrexate
Drug: cytarabine
Drug: ifosfamide
Drug: prednisone
Drug: vindesine

First Posted Date: 2008-06-04

Last Posted Date: 2009-07-08

Lead Sponsor: University Hospital Southampton NHS Foundation Trust

Target Recruit Count: 120

Registration Number: NCT00689845

Locations: 🇬🇧
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
🇬🇧
Christie Hospital, Manchester, England, United Kingdom
🇬🇧
Southampton General Hospital, Southampton, England, United Kingdom

and more 5 locations

Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy

Not Applicable

Terminated

Conditions: Osteosarcoma

Interventions: Drug: Doxorubicin
Drug: Cisplatin
Drug: Methotrexate
Drug: Leucovorin
Behavioral: Questionnaire
Drug: Dexrazoxane
Procedure: Surgery
Drug: Ifosfamide
Drug: Gemcitabine
Drug: Sargramostim
Drug: Mesna

First Posted Date: 2008-05-07

Last Posted Date: 2014-09-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00673179

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma

Phase 2

Conditions: Lymphoma
Small Intestine Cancer

First Posted Date: 2008-05-01

Last Posted Date: 2013-08-26

Lead Sponsor: Cancer Research UK

Target Recruit Count: 60

Registration Number: NCT00669812

Locations: 🇬🇧
Sir James Spence Institute of Child Health at Royal Victoria Infirmary, Newcastle-Upon-Tyne, England, United Kingdom

A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma

Phase 2

Completed

Conditions: Malignant Fibrous Histiocytoma (MFH) of Bone
Osteosarcoma

Interventions: Biological: Bevacizumab
Drug: Cisplatin
Drug: Doxorubicin
Drug: Methotrexate
Procedure: Surgery
Drug: Ifosfamide
Drug: etoposide
Radiation: Radiotherapy

First Posted Date: 2008-04-28

Last Posted Date: 2023-08-07

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 43

Registration Number: NCT00667342

Locations: 🇺🇸
Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
NCI/NIH - Pediatric Oncology Branch, Bethesda, Maryland, United States

and more 2 locations